Click to view your profile
Click to search for condition or expert
Click to open main menu
Diffuse Large B-Cell Lymphoma (DLBCL) Latest Advances
Find the Latest Research About Diffuse Large B-Cell Lymphoma (DLBCL)
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 02/19/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 211 publications
See more filters
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Condition:
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
The New England journal of medicine
Treatment Used:
Glofitamab
Number of Patients:
155
Published:
December 12, 2022
VIEW PUBLICATION
Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Frontiers in immunology
Treatment Used:
Zanubrutinib Plus Salvage Chemotherapy
Number of Patients:
27
Published:
December 12, 2022
VIEW PUBLICATION
Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon.
Condition:
Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with Hypopyon
Journal:
[Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used:
Busulfan/Thiotepa (BuTT) Followed by Autologous Peripheral Blood Stem Cell Transplantation
Number of Patients:
1
Published:
November 09, 2022
VIEW PUBLICATION
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System.
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
JCO global oncology
Treatment Used:
Rituximab
Number of Patients:
1807
Published:
November 09, 2022
VIEW PUBLICATION
Efficacy of Helicobater pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: A systematic review.
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL) of Stomach
Journal:
European journal of haematology
Treatment Used:
Helicobacter Pylori Eradication
Number of Patients:
152
Published:
September 29, 2022
VIEW PUBLICATION
ABCL-310 Triple Metachronous Malignancies in Primary Diagnosed Diffuse Large B-Cell Lymphoma Patient: A Case Report.
Condition:
Triple Metachronous Malignancies in Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Chemotherapy, Splenectomy, and Hemodialysis
Number of Patients:
1
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-398 Primary Breast Diffuse Large B-Cell Lymphoma: An Indian Experience.
Condition:
Primary Breast Diffuse Large B-Cell Lymphoma (PB-DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Multimodal Combination Therapy
Number of Patients:
18
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years.
Condition:
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Tafasitamab
Number of Patients:
80
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study.
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP)
Number of Patients:
879
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Condition:
Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Tafasitamab Plus Lenalidomide (LEN)
Number of Patients:
3454
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-320 Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL.
Condition:
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Loncastuximab Tesirine Combined with Rituximab (Lonca-R)
Number of Patients:
20
Published:
September 27, 2022
VIEW PUBLICATION
ABCL-452 First-Line Treatment With Subcutaneous Epcoritamab + R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update.
Condition:
High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Epcoritamab Plus R-CHOP
Number of Patients:
33
Published:
September 27, 2022
VIEW PUBLICATION
Showing 1-12 of 211
Next
Last Updated: 02/19/2023